Triple-negative breast cancer (TNBC) is characterized by complex genomic background and treatment resistance. We first defined “Titin (TTN) inactivation”, a state of TTN expression deficiency or mutation, affecting tumor progression. However, how TTN inactivation regulates immune escape and affects therapeutic resistance remains unclear. Using whole-exome sequencing, single-cell transcriptome sequencing, and spatial transcriptome sequencing, we screened the clinical features of TNBC patients with TTN inactivation who accepted neoadjuvant therapy. Meanwhile, we used CRISPR-Cas9 technology to construct various mutant TNBC cell lines. Lentiviral vector carrying TTN and delta-like ligand 4 (DLL4) was validated in vivo to verify potential mechanism. Myeloid-derived suppressor cells (MDSCs) metabolic function was measured using glycolysis-related molecular experiments. Immunotherapeutic agents against TNBC with TTN inactivation were explored in the orthotopic MCT4 fl/fl genetically modified mouse model. DLL4-regulated ecological niche was established in TNBC with TTN inactivation. Mechanistically, TTN deficiency and mutation led to DLL4 secretion in TNBC. DLL4 enhanced MCT4-mediated glycolysis via MDSCs-derived NOTCH2 signaling pathway, driving the malignant function and lactate acid excretion of MDSCs. DLL4-derived MDSCs promoted stemness-mediated drug resistance by inducing histone lactate modification in TNBC, suppressing the anti-tumor activities of CD8 + T cells. Blocking the DLL4-MCT4 axis stimulated anti-tumor immunity and synergized with anti-PD-1, improving response rates for first-line neoadjuvant therapy in TNBC. Our study revealed intrinsic mechanism by which TTN regulates the tumor immune microenvironment and provided a potential target for immunotherapy in TNBC with TTN inactivation.
13 January 2026 in International Journal of Surgery
Background: The AJCC 8th edition post-neoadjuvant pathologic stage (ypStage) shows limited prognostic discrimination in esophageal squamous cell carcinoma (ESCC). Alternative strategies have been proposed, but most were limited by small samples and lack of inclusion of patients treated with immunotherapy. This study aimed to validate the AJCC 8th edition ypStage and develop a refined ypStage system with improved prognostic performance for ESCC. Methods: This was a large retrospective cohort study including 1848 consecutive ESCC patients treated with neoadjuvant therapy followed by esophagectomy between June 2018 and September 2023. Patients were randomly assigned to training ( n = 1108) and validation ( n = 740) cohorts. A refined ypStage was developed using recursive partitioning analysis (RPA). Survival outcomes were evaluated using Kaplan-Meier curves and log-rank tests, and multivariable Cox proportional hazards regression was used to confirm independent prognostic value. Prognostic performance of the RPA and AJCC 8th edition ypStage systems was compared using the Groome criteria: hazard consistency, hazard discrimination, sample balance, outcome prediction, and overall score. Subgroup analyses were performed by neoadjuvant therapy type. Results: The AJCC 8th edition ypStage showed a reversal of the expected survival hierarchy between ypStage II and IIIA [3-year overall survival (OS): II, 80.1%; IIIA, 90.7%]. RPA identified three groups: ypStage I (ypT0-2N0-1), II (ypT0-2N2-3 or ypT3-4bN0-1), and III (ypT3-4bN2-3). In the validation cohort, RPA ypStage demonstrated clear survival separation (3-year OS: I, 91.2%; II, 79.1%; III, 60.5%; pairwise P < 0.01). Multivariable analysis confirmed its independent prognostic value [II vs I: Hazard Ratio (HR) = 2.44, 95% Confidence Interval (CI): 1.68–3.52; III vs I: HR = 3.67, 95% CI: 2.28–5.90; both P < 0.001]. RPA ypStage outperformed AJCC ypStage across all evaluation metrics. Subgroup analyses further supported its robustness, particularly in patients receiving chemotherapy or chemo-immunotherapy. Conclusion: The RPA-derived ypStage provides improved prognostic stratification compared with the AJCC 8th edition in ESCC patients following neoadjuvant therapy. Further external validation is warranted for potential incorporation into future staging guidelines.